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ttp://dx.doi.org/10.1016/j.ajpath.2012.08.043Chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infection affect >500 million people
worldwide and are signiﬁcant causes of liver cirrhosis and hepatocellular carcinoma. The patho-
genesis of HBV and HCV infection can vary widely with respect to the outcome of initial infection to
self-resolving acute or chronic disease, the extent of viremia and liver inﬂammation during chronic
infection, and the eventual development of liver cirrhosis and hepatocellular carcinoma. The host
immune response is an important factor in the variable consequences of these infections, because the
innate and adaptive intrahepatic antiviral responses are an intricate balance of immune effector cells
and cytokines that control virus replication but can also cause liver damage. IL-22 is an important
cytokine that plays a pleiotropic protective, but sometimes also pathological, role in several tissues/
organs, including the liver. Therefore, IL-22 is likely to be an important factor in the pathogenesis
and clinical outcome of HBV and HCV infection. However, the precise beneﬁcial, and possible
detrimental, effects of this cytokine may vary among different disease states that are associated with
distinct inﬂammatory microenvironments. This review summarizes our understanding of the
protective and pathological activities of IL-22, with an emphasis on the liver, and discusses the
implications of these effects as they relate to viral hepatitis. (Am J Pathol 2013, 182: 21e28; http://
dx.doi.org/10.1016/j.ajpath.2012.08.043)IL-22 and IL-22 Receptor Expression
IL-22 is a class II a-helical cytokine of the IL-10 cytokine
family, which is composed of nine immunomodulatory
proteins (IL-10, IL-19, IL-20, IL-22, IL-24, IL-26, IL-28A,
IL-28B, and IL-29). These nine family members are grouped
together on the basis of similarities among their encoding
genes, primary and secondary protein structures, and receptor
complexes. Despite these similarities, the IL-10 family
members have distinct functions, which are dictated, in part,
by differences in expression of their respective receptors. Thestigative Pathology.
.expression of the IL-22 receptor complex (IL-22 receptor
a subunit paired with IL-10 receptor b subunit) is restricted
to speciﬁc tissues, including hepatocytes and epithelial cells
of the gastrointestinal tract, skin, and lungs.1e3 Because the
IL-22 receptor is not expressed on immune cells, IL-22 has
no direct effects on immune cell function, but appears
to instead play an important role in regulating the conse-
quences of inﬂammation in IL-22esensitive tissues. The
effects of IL-22 have been best characterized in keratino-
cytes, hepatocytes, and colonic epithelial cells, where the
cytokine primarily signals through the STAT3 pathway.4
Table 1 Examples of IL-22 Protective and Pathogenic Actions
Activity by disease or model Tissue or cell Reference
Protective Actions
Extrahepatic
K. pneumoniae Lung 25
C. rodentium Intestine 26
Colitis Intestine 27e29
Airway inﬂammation Lung 30
Candidiasis GI tract 31e33
SIV GI tract 34
Intrahepatic
ConA hepatitis Hepatocytes 7, 8, 35, 36






T. gondii Intestine 42
Psoriasis Skin 43
Autoimmune CNS and synovium 44e46
Airway inﬂammation Lung 30
Intrahepatic
HBV Hepatocytes 47
HCC Tumor 8, 36, 48
CCL, chemokine ligand; CNS, central nervous system; GI, gastrointes-
tinal; HSC, hepatic stellate cell; LPC, liver progenitor cell; SIV, simian
immunodeﬁciency virus.
Cobleigh and RobekDownstream IL-22 signaling in these tissues leads to the
expression of acute inﬂammatory proteins,5,6 activation of
proliferative and anti-apoptotic programs,7,8 and induction of
antimicrobial genes and cytokines/chemokines.9,10
Among the IL-10 family cytokines, IL-22, in particular,
shares several structural and other similarities with the type
III interferons [IL-29, IL-28A, and IL-28B, alias interferon
(IFN)-l1, IFN-l2, and IFN-l3, respectively]. The crystal
structure of IFN-l3 revealed that it has a higher level of
structural similarity to IL-22 than to the type I interferons.11
Furthermore, similar to IL-22, IFN-l signals through a het-
erodimeric receptor complex consisting of both a unique
subunit (IL-28 receptor a) and the IL-10 receptor b subunit,
which it shares with IL-10, IL-22, and IL-26. Similar to the
IL-22 receptor a subunit, IL-28 receptor a has a restricted
expression proﬁle, and is strongly expressed on intestinal
epithelial cells and hepatocytes.12,13 These unique receptor
subunits are encoded in adjacent loci on chromosome
1p36.11. Both cytokines play a role in defense against
infection at epithelial barriers, suggesting that the two may
have evolved as part of an innate system to provide
protection in tissues that are highly susceptible to infec-
tion.11 Nevertheless, these functions appear to be distinct,
because IFN-l and IL-22 induce different patterns of gene
expression. For example, in hepatocytes, IFN-l activates
STAT1 and induces a transcriptional response more similar
to IFN-a/b and IFN-g, whereas IL-22 activates STAT3 and
induces a gene expression program more similar to the
acute-phase response elicited by IL-6.14
Both innate and adaptive immune responses can
contribute to the production of IL-22. IL-22 is expressed by
CD4þ T cells, of which several subsets are particularly
important. T helper (Th)17 cells abundantly express IL-22,
in addition to IL-17A, IL-17F, IL-26, and chemokine ligand
20, whereas Th22 cells express IL-22 but not IL-17
(A/F).15e19 Similarly, a subset of gd T cells expresses both
IL-17A and IL-22 immediately on IL-23 stimulation.20 In
addition to T cells, several innate lymphoid cells (ILCs) are
important sources of IL-17A and/or IL-22.21 These include
a subset of natural killer cells that highly express IL-22
and populations of lymphoid tissueeinducer cells that
express the Th17 transcription factor RORgt.21e23 Although
ILCs are best characterized for their roles in lymphoid organ
formation and intestinal immunity, they have also been
found in inﬂamed liver tissue.24 Given the multiple cell
types that express IL-22, it is likely that the speciﬁc in vivo
cellular source of IL-22 in a speciﬁc inﬂammatory process
varies, depending on the speciﬁc tissue and disease state in
which it is expressed.
IL-22 in Extrahepatic Immune Responses
A number of studies have described various situations in
which IL-22 production is elevated, primarily during inﬂam-
mation or infection. Interestingly, these studies indicate that
IL-22 may play dual roles, protective or pathogenic,22depending on the context in which it is expressed (Table 1).
More important, at many epithelial barrier surfaces, IL-22
expression is protective against infection and inﬂammation.
This is likely due, in part, to IL-22edependent induction of
antimicrobial proteins, including b-defensin, psoriasin, mucin,
regenerating islet-derived protein III, and calgranulins A and B
at these barrier surfaces.1,10,26e28 For example, IL-22 restricts
replication and dissemination of the bacteria Klebsiella
pneumoniae and Citrobacter rodentium in the lung and
intestine, respectively. Infection with either pathogen in IL-
22edeﬁcient mice leads to rapid mortality, demonstrating that
an innate IL-22einduced response is essential for protective
immunity during these infections.25,26 Furthermore, the
importance of IL-22einduced protective immunity is sup-
ported by evidence demonstrating higher mucosal infection
rates in patient populations with deregulated IL-22 function.
Job’s syndrome is characterized by a hypomorphic mutation in
the STAT3 gene and lower IL-22 production, and these patients
experience severe and recurrent secondary infections in the
lung, skin, and intestine.31 Similarly, patients with autoim-
mune polyendocrine syndrome 1 have high levels of autoan-
tibodies against IL-17A, IL-17F, and IL-22, which correlates
with chronic mucocutaneous candidiasis.31,32 In fact, addi-
tional studies demonstrated that protective immunity to
candidiasis involves an early, IL-22edominated response,
which controls initial fungal growth and tissue homeostasis
during infection.33ajp.amjpathol.org - The American Journal of Pathology
IL-22 in Viral HepatitisIn addition to its antimicrobial properties, IL-22 can
also regulate genes responsible for cell proliferation,
survival, and tissue repair, consistent with its protective
roles in certain contexts, especially the gut. Along with
activating proinﬂammatory gene transcription, IL-22
signaling in intestinal epithelial cells also induces the
migration of these cells, which is important for wound
healing and maintenance of the intestinal barrier.49 Further
supporting the role of IL-22 in cell proliferation and tissue
repair, delays in mucosal wound healing were observed in
colonic biopsy specimens obtained from IL-22edeﬁcient
mice compared with their wild-type counterparts, thus
demonstrating that IL-22 promotes wound healing in
vivo.27 Also consistent with its tissue-protective proper-
ties, IL-22 is protective in both innate and T-celledriven
colitis animal models, suggesting that IL-22 secretion by
both CD4þ T cells and natural killer cells in the colon can
mediate protection.29 Loss of IL-22eproducing mucosal
lymphocyte populations from simian immunodeﬁciency
viruseinfected rhesus macaques is also associated with
damage to the tight epithelial barrier of the gastrointestinal
tract.34 Furthermore, IL-22 gene delivery rapidly reduces
local intestinal inﬂammation in a mouse model of ulcer-
ative colitis, and IL-22emediated tissue repair was
achieved by enhancing mucus production through
STAT3-dependent expression of the mucus-associated
molecules, mucins 1, 3, 10, and 13.28 Finally, genetic
evidence supports a role for IL-22 in inﬂammatory bowel
disease, as a risk loci for ulcerative colitis has been
identiﬁed in the 12q14 chromosome region encoding IFN-
g, IL-26, and IL-22,50 and increased serum IL-22 levels in
patients with Crohn’s disease are associated with IL23R
gene variants that are linked to an increased risk of
developing this disease.51
However, in contrast to its antimicrobial and tissue-
protective properties, IL-22 can play a proinﬂammatory role
in some disease processes. Systemic administration of
exogenous IL-22 alone is sufﬁcient to promote inﬂamma-
tion. In mice, i.p. delivery of IL-22 protein or infection with
a recombinant adenovirus that expresses IL-22 induces
changes indicative of an acute-phase response, including the
induction of ﬁbrinogen, CXCL1, and serum amyloid A,
along with changes in platelet, neutrophil, and red blood cell
counts, body weight, and renal proximal tubule metabo-
lism.52 Highlighting the potential context-dependent nature
of IL-22 function, some of these IL-22emediated systemic
inﬂammatory effects may be dependent on the amount of
IL-22, because they were not observed in another study that
administered a lower dose of adenovirus IL-22 expression
vector to mice.37 Unlike its protective role against infection
with K. pneumoniae and C. rodentium, IL-22 plays a path-
ogenic role during oral infection with Toxoplasma gondii.42
During T. gondii infection, mice treated with an anti-IL-22
antibody had signiﬁcantly less intestinal pathological char-
acteristics than their control antibody-treated counterparts,
even though parasite burdens were similar between the twoThe American Journal of Pathology - ajp.amjpathol.orggroups. Furthermore, local induction of IL-22 expression
results in keratinocyte migration, epidermal hyperplasia, and
dermal inﬂammation43 and may, therefore, be a key medi-
ator in the pathogenesis of psoriasis.
IL-22 may also play a proinﬂammatory, pathogenic role
in some autoimmune diseases. IL-22 is expressed by
CD45ROþ CD4 T cells in the brain of individuals with
multiple sclerosis, and can mediate disruption of tight
junctions, leading to permeabilization of the blood-brain
barrier.44 This indicates that IL-22 may play a pathogenic
role in this disorder, because it may potentiate the trafﬁcking
of peripheral autoreactive T cells into the central nervous
system.44 Furthermore, increases in IL-22 expression have
also been correlated with the chronic inﬂammatory disease
rheumatoid arthritis.45 Synovial ﬁbroblasts derived from
patients with rheumatoid arthritis undergo increases in
proliferation and production of the chemokine ligand 2 after
treatment with IL-22, suggesting a proinﬂammatory role for
the cytokine in this disease process. The pathogenic role of
IL-22 during rheumatoid arthritis is further supported in
a mouse model of arthritis in which IL-22 deﬁciency results
in a less severe disease course and decreased mRNA
expression of the inﬂammatory markers IL-1b, IL-6, tumor
necrosis factor-a, matrix metalloproteinase-9, and IL-17A in
the synovium.46
Given the seemingly paradoxical dual nature of IL-22 in
modulating tissue immune responses, the effects that it
exerts are likely dependent on the speciﬁc context in which
the cytokine is expressed. For instance, it was recently
shown that IL-17A regulates the pathogenic and protective
functions of IL-22 in airway inﬂammation.30 Coexpressed
with IL-17A, IL-22 acts synergistically to promote chemo-
kine expression, neutrophil recruitment, and airway
inﬂammation. However, in the absence of IL-17A coex-
pression, IL-22 strengthened the integrity of the lung
epithelial barrier, thereby functioning in a tissue-protective
manner. Furthermore, despite the induction of antimicrobial
protein expression and protective effects of IL-22 during
K. pneumoniae and C. rodentium infection, IL-22 is
proinﬂammatory in the intestine after oral infection with
T. gondii.53 Taken together, these studies suggest that the
inﬂammatory microenvironment within tissues plays a crit-
ical role in the function of IL-22.Protective Actions of IL-22 in the Liver
At present, most studies support a clear protective role for IL-
22 in the prevention of hepatocellular damage, although there
is evidence indicating dual protective and pathogenic roles
for the cytokine in this organ as well. IL-22 promotes hepa-
tocyte growth and migration in cell culture,8,54 and expres-
sion of IL-22 in the liver protects hepatocytes in a variety of
tissue damage models. In mouse models of T-celledepend-
ent hepatitis [concanavalin A (ConA) injection, murine
cytomegalovirus infection], IL-22 expression is signiﬁcantly23
Cobleigh and Robekinduced in the liver.8,54 On IL-22 blockade with neutralizing
antibody, ConA-mediated liver injury increases while
STAT3 activation decreases, and injection of recombinant
IL-22 protein in this model reduces hepatocellular damage.8
Additional studies demonstrated that IL-22edeﬁcient mice
are also highly sensitive to liver injury caused by ConA-
mediated hepatitis.35 Adoptive transfer of IL-22eexpressing
Th17 cells into IL-22/ mice resulted in a reduction of
serum alanine aminotransferase (ALT) and aspartate
aminotransferase levels after ConA injection, indicating that
IL-22 provides protection against liver damage in this model.
Further supporting the protective role of IL-22, recent work
demonstrated that liver-speciﬁc IL-22etransgenic mice are
resistant to ConA-induced hepatitis.36 The overexpression of
IL-22 in these mice also accelerated liver regeneration after
partial hepatectomy, while having minimal effects on liver
inﬂammation.36 In addition to providing protection against
ConA-mediated hepatitis, hydrodynamic gene delivery of
IL-22 to the liver protects against hepatocellular injury,
necrosis, and apoptosis after carbon tetrachloride and
Fas ligandeinduced damage.7 Finally, bile acideinduced
apoptosis of steatotic hepatocytes is also accompanied by an
increase in IL-22 mRNA expression, further implicating
IL-22 in a liver-speciﬁc response to cellular damage.55
IL-22 treatment also ameliorates alcoholic fatty liver,
liver damage, and hepatic oxidative stress in a mouse model
of alcohol-induced liver injury, and deletion of STAT3 from
hepatocytes eliminates the hepatoprotection provided by IL-
22 in this model.37 Because of its ability to induce anti-
apoptotic and mitogenic protein expression through STAT3
activation, these ﬁndings support the role of IL-22 as
a hepatocellular survival factor against toxin-induced liver
injury. Further conﬁrming the hepatoprotective role of IL-
22, recent ﬁndings in patients with chronic hepatitis B virus
(HBV) infection demonstrate that IL-22eexpressing cells
colocalize with liver progenitor cells. In patients with
chronic HBV, IL-22 expressed from CD3þ T cells promoted
liver progenitor cell proliferation, which was again depen-
dent on STAT3 activation.38
After liver injury, the activation of hepatic stellate cells
and the accumulation of extracellular matrix proteins result
in liver ﬁbrosis. Several studies have examined the associ-
ation between IL-22 and liver ﬁbrosis in humans and
mice.39e41 Intrahepatic IL-22 expression negatively corre-
lates with ﬁbrosis stage in the liver of patients with chronic
hepatitis B,53 and administration of IL-22 decreases hepatic
ﬁbrosis in mice.39,40 Hepatic stellate cells express high
levels of the IL-22 receptor complex, and IL-22 induces
senescence of these cells via activation of STAT3, SOCS3,
and p53, thus reducing liver ﬁbrosis.39Pathogenic Activities of IL-22 in the Liver
By using a transgenic mouse model of HBV replication in
the liver, we recently demonstrated that IL-22 neutralization24ameliorates liver damage after transfer of HBV-speciﬁc
T cells.47 Furthermore, IL-22 neutralization signiﬁcantly
reduced chemokine expression and the subsequent recruit-
ment of inﬂammatory cells into the liver. Taken together,
these studies suggest that, in certain contexts, IL-22 may
directly or indirectly contribute to liver disease pathogenesis
by promoting the migration of inﬂammatory cells into the
liver, which can increase T-celleinduced hepatocyte
injury.56
Although this potential proinﬂammatory role of IL-22
in the liver may seem paradoxical to its well-established
protective role, one function is not necessarily mutually
exclusive of the other. In fact, distinctions between the
model systems used to study the role of IL-22 in the liver
may provide important clues to its physiological roles in
different disease states. For example, unlike chemically
induced liver injury, the liver inﬂammation and subse-
quent elevation of ALT levels in the HBV-transgenic
mouse T-cell adoptive transfer model are potentiated by
recruitment of inﬂammatory cells into the liver. This
recruitment requires speciﬁc cellular and protein media-
tors, including neutrophils, chemokines, and matrix
metalloproteinases,56,57 all of which can be induced by
IL-22.9,52 IL-22 also increases the proinﬂammatory
activity of tumor necrosis factor-a,15 which is expressed
in the liver after transfer of HBV-speciﬁc T cells. In total,
these factors may all contribute to the proinﬂammatory
effect of IL-22 in this particular model.
Another potentially deleterious effect of IL-22 expres-
sion relates to its ability to promote liver tumor cell growth,
which has been observed both in vitro8 and in vivo.36,48
Tumor-inﬁltrating lymphocytes from patients with hepa-
tocellular carcinoma (HCC) display elevated IL-22
expression, and these IL-22þ lymphocytes promote HCC
tumor growth and metastasis in mice.48 Additional studies
have demonstrated, however, that IL-22 overexpression
alone in transgenic mice is not sufﬁcient for the develop-
ment of HCC, although these same mice are more
susceptible to diethylnitrosamine-induced liver cancer.36
Consistent with these ﬁndings, diethylnitrosamine-treated
IL-22edeﬁcient mice display reduced tumorigenesis.48
These results indicate that the proliferative and anti-
apoptotic activities of IL-22 may accelerate the growth of
existing HCCs.36Consequences for Viral Hepatitis
IL-22 expression is up-regulated in the liver of patients
with chronic HBV and hepatitis C virus (HCV) infec-
tion.36,41,54,58,59 Furthermore, patients with HBV infec-
tion display increased percentages of Th17 cells, a major
producer of IL-22, in peripheral blood and liver, and
increased concentrations of IL-22 in serum.41,47,60 Simi-
larly, Th17 cells are also found in the liver of patients
with chronic HCV.59,61 However, consistent with the factajp.amjpathol.org - The American Journal of Pathology
Figure 1 Protective versus pathological effects of IL-22 in viral
hepatitis. IL-22, expressed by Th17 cells, Th22 cells, or liver-resident
ILCs, can have dual protective and pathogenic hepatocellular effects.
Although Th17 cells are found in the liver of patients with chronic
HBV and HCV infection, the presence of intrahepatic Th22 cells and
ILCs is not deﬁned. IL-22 can increase hepatocyte proliferation,
inhibit apoptosis, stimulate liver progenitor cells, and down-regulate
ﬁbrosis. Conversely, IL-22 may also up-regulate chemokine and matrix
metalloproteinase expression, and promote neutrophil migration in the
liver. IL-22 may also promote the development of HCC. The balance
between these two seemingly paradoxical functions may be dependent
on the tissue microenvironment present during different disease and
inﬂammation states.
IL-22 in Viral Hepatitisthat IL-22 does not induce expression of traditional IFN-
stimulated antiviral proteins, such as MxA and 2050-OAS
in hepatocytes,14,58 IL-22 has only minor direct antiviral
effects on HBV14 or HCV58 replication in cell culture, or
on HBV replication in transgenic mice.47 Furthermore,
IL-22 does not affect the antiviral activity of IFN-l in
hepatocytes, a cytokine with which it shares the IL-10
receptor b subunit.14 Thus, the inﬂuences of IL-22 on
HBV and HCV infection do not appear to include direct
antiviral effects. Nevertheless, similar to other inﬂam-
matory conditions, such as Crohn’s disease and ulcerative
colitis, genetic evidence supports a role for IL-22 in HCV
infection, because single-nucleotide polymorphisms in the
IL-22 gene inﬂuence treatment response and viral
clearance.62
Because of the difﬁculties in ascribing mechanistic func-
tions from correlative data in humans, it is unclear whether
IL-22 up-regulation is protective or proinﬂammatory in HBV
and HCV infection. For example, although IL-22 expression
in the liver is positively correlated with serum ALT levels,36
this may be indicative of a compensatory mechanism that,
rather than causing damage, is preventing further injury.
Based on the number of ﬁndings supporting both protective
and proinﬂammatory roles for IL-22 in other tissues, it is
tempting to speculate that the function of IL-22 may be
dictated by the speciﬁc microenvironment within the liver as
well, with the net result being a reﬂection of the balance
between these functions (Figure 1). For instance, IL-22 may
play a proinﬂammatory role during acute HBV infection,
perhaps to amplify immune cell inﬁltration and clearance of
virus, whereas it may play a more protective role during
chronic HBV infection, compensating for long-term inﬂam-
matory damage by promoting hepatocellular proliferation
and survival.
However, even during chronic HBV infection, IL-22 may
be mainly protective in some situations, yet pathogenic in
others. Chronic hepatitis B is a complex heterogeneous
disease that progresses through different phases of immune
tolerance (high HBV and low ALT), immune activity (high
HBV and high ALT), and immune inactivity (low HBV and
low ALT). In fact, IL-22 expression levels may correlate
with either high or low ALT levels,36,41 suggesting that
perhaps the balance between its dual protective and proin-
ﬂammatory effects can be tipped throughout chronic HBV
infection.Summary and Perspectives
Despite signiﬁcant progress, the mechanisms underlying
HBV and HCV persistence and pathogenesis remain rela-
tively poorly deﬁned. A tremendous amount has been
learned about IL-22 in the 12 years since its discovery, but
the diverse and pleiotropic nature of its activity has made
a precise determination of its function challenging, and there
is still much that we do not understand about the role of thisThe American Journal of Pathology - ajp.amjpathol.orgfascinating cytokine in viral hepatitis and other diseases. To
more thoroughly characterize the intrahepatic determinants
that inﬂuence IL-22 function in chronic HBV and HCV
infection, it will be necessary to use large human patient
populations with well-deﬁned clinical disease characteristics
and to employ more physiological animal models of virus
infection, such as humanized mice. A thorough character-
ization of intrahepatic IL-22eproducing cells, including
Th17 cells, Th22 cells, or ILCs, and their role in chronic25
Cobleigh and RobekHBV- and HCV-associated liver disease, is another critical
area for future research. A better understanding of the
intrahepatic microenvironments that inﬂuence the patho-
logical versus protective effects of IL-22 will be signiﬁcant
for the development of new immunotherapeutic approaches
that target IL-22 or IL-22eproducing cells.
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